MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Cited by (1,001)

Items 101–200 of 1,001

1. The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
   Tanguy Y. Seiwert, Ramasamy Jagadeeswaran, Leonardo Nercolini Faoro, Varalakshmi Janamanchi, Vidya Nallasura, Mohamed El Dinali, Soheil Yala, Rajani Kanteti, Ezra E.W. Cohen, Mark William Lingen et al. · 2009 · Cancer Research
2. Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells
   Kazuhiko Shien, Shinichi Toyooka, Hiromasa Yamamoto, Junichi Soh, Masaru Jida, Kelsie L. Thu, Shinsuke Hashida, Yuho Maki, Eiki Ichihara, Hiroaki Asano et al. · 2013 · Cancer Research
3. VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
   Weon‐Kyoo You, Barbara Sennino, Casey W. Williamson, Beverly L. Falcón, Hiroya Hashizume, Li‐Chin Yao, Dana T. Aftab, Donald M. McDonald · 2011 · Cancer Research
4. Targeting adaptive glioblastoma: an overview of proliferation and invasion
   Qian Reuben Xie, Sandeep Mittal, Michael E. Berens · 2014 · Neuro-Oncology
5. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
   Sandra Ortiz‐Cuaran, Matthias Scheffler, Dennis Plenker, llona Dahmen, Andreas Hans Scheel, Lynnette Fernandez‐Cuesta, Lydia Meder, Christine Marie Lovly, Thorsten Persigehl, Sabine Merkelbach‐Bruse et al. · 2016 · Clinical Cancer Research
6. Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
   Matthew J. Niederst, Jeffrey A. Engelman · 2013 · Science Signaling
7. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
   Yi-Long Lung Cancer Wu, Ying Cheng, Jianying Zhou, Shun Lü, Yiping Zhang, Jun Zhao, Dong‐Wan Kim, Ross Andrew Soo, Sang‐We Kim, Hongming Pan et al. · 2020 · The Lancet Respiratory Medicine
8. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
   Raymond A. Pagliarini, Wenlin Shao, William R. Sellers · 2015 · EMBO Reports
9. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
   Martin L. Sos, Stefanie Fischer, Roland Tillmann Ullrich, Martin Peifer, Johannes M. Heuckmann, Mirjam Koker, Stefanie Heynck, Isabel Stückrath, Jonathan M. Weiss, Florian Fischer et al. · 2009 · Proceedings of the National Academy of Sciences
10. Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer
    Christine A. Pratilas, Aphrothiti J. Hanrahan, Ensar Halilovic, Yogindra Persaud, Junichi Soh, Dhananjay Arun Chitale, Hisayuki Shigematsu, Hiromasa Yamamoto, Ayana Sawai, Manickam Janakiraman et al. · 2008 · Cancer Research
11. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
    Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Cells
12. Targeted therapy in cancer
    Apostolia Maria Tsimberidou · 2015 · Cancer Chemotherapy and Pharmacology
13. Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
    Filip Jankú, David J. Stewart, Razelle Kurzrock · 2010 · Nature Reviews Clinical Oncology
14. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
    K E Ware, Trista K. Hinz, Emily K. Kleczko, Katherine R. Singleton, Lindsay A. Marek, Barb Helfrich, Christopher T. Cummings, Douglas K. Graham, David P. Astling, Aik Choon Tan et al. · 2013 · Oncogenesis
15. NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma
    Yamaguchi, Tomoya, Yanagisawa, Kiyoshi, Sugiyama, Ryoji, Hosono, Yasuyuki, Shimada, Yukako, Arima, Chinatsu, Kato, Seiichi, Tomida, Shuta, Suzuki, Motoshi, Osada, Hirotaka et al. · 2012 · Cancer Cell
16. Molecular Biology of Lung Cancer: Clinical Implications
    Jill E. Larsen, John Dorrance Minna · 2011 · Clinics in Chest Medicine
17. Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
    Chih-Hsin Yang, Chong‐Jen Yu, Jin‐Yuan Shih, Yeun‐Chung Chang, Fu‐Chang Hu, Meng-Chi Tsai, Kuan‐Yu Chen, Zhong‐Zhe Lin, Ching-Ju Huang, Chia‐Tung Shun et al. · 2008 · Journal of Clinical Oncology
18. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
    Fu, Jianjiang, Su, Xiaorui, Li, Zhihua, Deng, Ling, Liu, Xiawei, Feng, Xuancheng, Peng, Juan · 2021 · Oncogene
19. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
    Helena Linardou, Issa J Dahabreh, Dimitrios I. Bafaloukos, P. Kosmidis, Samuel J. Murray · 2009 · Nature Reviews Clinical Oncology
20. Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
    Yanan Kuang, Andrew M. Rogers, Beow Yong Yeap, Lilin Wang, Mike G. Makrigiorgos, Kristi Vetrand, Sara Thiede, Robert J. Distel, Pasi Antero Janne · 2009 · Clinical Cancer Research
21. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
    Jose Rafael Sierra, Virna Cepero, Silvia Giordano · 2010 · Molecular Cancer
22. Biology and evolution of poorly differentiated neuroendocrine tumors
    David S. Rickman, Himisha Beltran, Francesca Demichelis, Mark A. Rubin · 2017 · Nature Medicine
23. Targeting tumour-supportive cellular machineries in anticancer drug development
    Matthias Dobbelstein, Ute Martha Moll · 2014 · Nature Reviews Drug Discovery
24. EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
    Kenichi Suda, Ryoichi Onozato, Yasushi Yatabe, Tetsuya Mitsudomi · 2009 · Journal of Thoracic Oncology
25. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
    Di Zheng, Xue-Rui Ye, M. Z. Zhang, Yun Sun, J. Y. Wang, Jian Ni, H. P. Zhang, L. Zhang, Jie Luo, J. Zhang et al. · 2016 · Scientific Reports
26. Molecular pathways and therapeutic targets in lung cancer
    Shtivelman, Emma, Hensing, Thomas, Simon, George R., Dennis, Phillip A., Otterson, Gregory A., Bueno, Raphael, Salgia, Ravi · 2014 · Oncotarget
27. Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
    Seiji Yano, Tadaaki Yamada, Shinji Takeuchi, Keisei Tachibana, Yuko Minami, Yasushi Yatabe, Tetsuya Mitsudomi, Hidenori Tanaka, Tatsuo Kimura, Shinzoh Kudoh et al. · 2011 · Journal of Thoracic Oncology
28. High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
    Heounjeong Go, Yoon Kyung Jeon, Hyo Jin Park, Sook-Whan Sung, Jeong‐Wook Seo, Doo Hyun Chung · 2010 · Journal of Thoracic Oncology
29. Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
    Jie Qi, Michele A. McTigue, Andrew M. Rogers, Eugene Lifshits, James G. Christensen, Pasi Antero Janne, Jeffrey A. Engelman · 2011 · Cancer Research
30. Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer
    Elizabeth A. Buck, Prafulla C. Gokhale, Susan Koujak, Eric Brown, Alexandra Eyzaguirre, Nianjun Tao, Maryland Rosenfeld-Franklin, Lorena R. Lerner, Maria Isabel Chiu, Robert Wild et al. · 2010 · Molecular Cancer Therapeutics
31. Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
    Ryohei Katayama, Aki Aoyama, Takao Yamori, Jie Qi, Tomoko Oh‐hara, Youngchul Song, Jeffrey A. Engelman, Naoya Fujita · 2013 · Cancer Research
32. Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
    Vassiliki A. Papadimitrakopoulou · 2012 · Journal of Thoracic Oncology
33. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
    Neelu Puri, Ravi Salgia · 2008 · Journal of Carcinogenesis
34. Crosstalk in Met receptor oncogenesis
    Andrea Z. Lai, Jasmine V. Abella, Morag Park · 2009 · Trends in Cell Biology
35. Precision medicine in non-small cell lung cancer: Current applications and future directions
    Soo‐Ryum Yang, Anne Maria Schultheis, Helena Alexandra Yu, Diana L. Mandelker, Marc Ladanyi, Reinhard Büttner · 2020 · Seminars in Cancer Biology
36. Molecular biology of lung cancer: Clinical implications
    Kwun Meng Fong, John Dorrance Minna · 2002 · Clinics in Chest Medicine
37. Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
    Manish A. Shah, Zev A. Wainberg, Daniel V.T. Catenacci, Howard S. Höchster, James M. Ford, Pamela L. Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C. Rabe et al. · 2013 · PLoS ONE
38. The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
    Christiane R. Maroun, Tracey M. Rowlands · 2014 · Pharmacology & Therapeutics
39. Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
    Hideki Terai, Kenzo Soejima, Hiroyuki Yasuda, Sohei Nakayama, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Shinnosuke Ikemura, Takashi Sato et al. · 2013 · Molecular Cancer Research
40. Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
    Kenichi Suda, Isao Murakami, Tatsuya Katayama, Kenji Tomizawa, Hirotaka Osada, Yoshitaka Sekido, Yoshihiko Maehara, Yasushi Yatabe, Tetsuya Mitsudomi · 2010 · Clinical Cancer Research
41. Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
    Elza C. de Bruin, Catherine Cowell, Patricia H. Warne, Ming Zuo Jiang, Rebecca E. Saunders, Mary Ann Melnick, Scott N. Gettinger, Zenta Walther, Anna Wurtz, Guus J.J.E. Heynen et al. · 2014 · Cancer Discovery
42. The emerging role of MET/HGF inhibitors in oncology
    Giorgio V. Scagliotti, Silvia Novello, Joachim von Pawel · 2013 · Cancer Treatment Reviews
43. A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
    Funda Meric‐Bernstam, Amber M. Johnson, Vijaykumar R. Holla, Ann Marie Bailey, Lauren Brusco, Ken Chen, Mark J. Routbort, Keyur Pravinchandra Patel, Jia Zeng, Scott Kopetz et al. · 2015 · JNCI Journal of the National Cancer Institute
44. Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancer
    Katsuhiro Okuda, Hidefumi Sasaki, Haruhiro Yukiue, Motoki Yano, Yoshitaka Fujii · 2008 · Cancer Science
45. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
    Yuxin Lin, Xian Wang, Hongchuan Jin · 2014 · Europe PMC (PubMed Central)
46. The two sides of chromosomal instability: drivers and brakes in cancer
    Rendy Hosea, Sharon Hillary, Sumera Naqvi, Shourong Wu, Vivi Kasim · 2024 · Signal Transduction and Targeted Therapy
47. MET As a Possible Target for Non–Small-Cell Lung Cancer
    Ahad Ali Sadiq, Ravi Salgia · 2013 · Journal of Clinical Oncology
48. Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Eric Santoni‐Rugiu, Linea Cecilie Melchior, Edyta Maria Urbanska, Jan Nyrop Jakobsen, Karin de Stricker, Morten Grauslund, Jens Benn Sørensen · 2019 · Cancers
49. The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients
    Lecia Van Dam Sequist, Sunitha Nagrath, Mehmet Toner, Daniel A. Haber, Thomas James Lynch · 2009 · Journal of Thoracic Oncology
50. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
    Weon‐Kyoo You, Donald M. McDonald · 2008 · BMB Reports
51. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology
    Amit J. Sabnis, Trever Grant Bivona · 2019 · Trends in Molecular Medicine
52. Prognostic and Predictive Biomarkers: Tools in Personalized Oncology
    Ewelina Nalejska, Ewa Mączyńska, Marzena Anna Lewandowska · 2014 · Molecular Diagnosis & Therapy
53. MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung
    Hans‐Ulrich Schildhaus, Anne Maria Schultheis, Josef Rüschoff, Elke Binot, Sabine Merkelbach‐Bruse, Jana Fassunke, Wolfgang Schulte, Yon‐Dschun Ko, Andreas Schlesinger, Marc Christiaan Allardt Bos et al. · 2014 · Clinical Cancer Research
54. Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis
    Elisa Benedettini, Lynette Marie Sholl, Michael Peyton, John F. Reilly, Christopher M. Ware, Lenora J. Davis, Natalie Vena, Dyane Bailey, Beow Yong Yeap, Michelangelo Fiorentino et al. · 2010 · American Journal Of Pathology
55. Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
    Zhe Tang, Ruikai Du, Shan Jiang, Chan Wu, Deborah Sim Barkauskas, John S. Richey, Joseph P. Molter, M Lam, Chris A. Flask, Stanton L. Gerson et al. · 2008 · British Journal of Cancer
56. Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
    Soundararajan Krishnaswamy, Rajani Kanteti, Jonathan S. Duke‐Cohan, Sivakumar Loganathan, Wanqing Liu, Patrick C. Ma, Martin Sattler, Patrick A. Singleton, Nithya Ramnath, Federico Innocenti et al. · 2009 · Clinical Cancer Research
57. Novel therapeutic targets on the horizon for lung cancer
    Wan-Ling Tan, Amit Jain, Angela Maria Takano, Evan William Newell, Narayanan Gopalakrishna Iyer, Wan‐Teck Lim, Eng-Huat Tan, Weiwei Zhai, Axel M. Hillmer, Wai Leong Tam et al. · 2016 · The Lancet Oncology
58. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
    Ou, Sai-Hong Ignatius · 2012 · Critical Reviews in Oncology/Hematology
59. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma
    Akiko Kawano Nagatsuma, Masaki Aizawa, Takeshi Kuwata, Toshihiko Doi, Atsushi Ohtsu, Hirofumi Fujii, Atsushi Ochiai · 2014 · Gastric Cancer
60. Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options
    Meysam Yousefi, Tayyeb Bahrami, Arash Salmaninejad, Rahim Nosrati, Parisa Ghaffari, Seyed Hamidollah Ghaffari · 2017 · Cellular Oncology
61. MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment
    Kentaro Inamura, Yuichi Ishikawa · 2016 · Journal of Clinical Medicine
62. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
    Nilsson, Monique B., Sun, Huiying, Robichaux, Jacqulyne, Pfeifer, Matthias, McDermott, Ultan, Travers, Jon, Diao, Lixia, Xi, Yuanxin, Tong, Pan, Shen, Li et al. · 2020 · Science Translational Medicine
63. Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations
    Riyaz N.H. Shah, Jason Francis Lester · 2019 · Clinical Lung Cancer
64. HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
    Liska, David, Chen, Chin-Tung, Bachleitner-Hofmann, Thomas, Christensen, James G., Weiser, Martin R. · 2011 · Clinical Cancer Research
65. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges
    Xiangdong Liu, Robert Charles Newton, Peggy Scherle · 2009 · Trends in Molecular Medicine
66. Mechanism of Cell Adaptation
    Valentina Fodale, Mariaelena Pierobon, Lance A. Liotta, Emanuel Petricoin · 2011 · The Cancer Journal
67. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
    Sau-Chi Betty Yan, Victoria L. Peek, Rose T. Ajamie, Sean G. Buchanan, Jeremy Richard Graff, Steven A. Heidler, Yu‐Hua Hui, Karen L. Huss, Bruce W. Konicek, Jason R. Manro et al. · 2012 · Investigational New Drugs
68. Targeting EGFR ^L858R/T790M and EGFR ^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry
    Lu, Xiaoyun, Yu, Lei, Zhang, Zhang, Ren, Xiaomei, Smaill, Jeff B., Ding, Ke · 2018 · Medicinal Research Reviews
69. Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
    Sinead A. Noonan, Lynne D. Berry, Xian Jun David Lu, Dexiang Gao, Anna E. Barón, Patrick Chesnut, Jamie E. Sheren, Dara L. Aisner, Dan Merrick, Robert Charles Doebele et al. · 2016 · Journal of Thoracic Oncology
70. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways
    James Andrew McCubrey, Linda S. Steelman, Christian Kempf, William H. Chappell, Stephen Lee Abrams, Franca Stivala, Graziella Malaponte, Ferdinando Nicoletti, Massimo Libra, Jörg Bäsecke et al. · 2011 · Journal of Cellular Physiology
71. Effects of Erlotinib in <i>EGFR</i> Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
    Costa, Daniel B., Nguyen, Kim-Son H., Cho, Byoung C., Sequist, Lecia V., Jackman, David M., Riely, Gregory J., Yeap, Beow Y., Halmos, Balázs, Kim, Joo H., Jänne, Pasi A. et al. · 2008 · Clinical Cancer Research
72. Mechanisms of action of therapeutic antibodies for cancer
    Jason Mark Redman, Elizabeth Hill, Dalal S. Aldeghaither, Louis M. Weiner · 2015 · Molecular Immunology
73. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
    Joost Neijssen, Rosa M. F. Cardoso, Kristen M. Chevalier, Luus Wiegman, Thomas Valerius, G. Mark Anderson, Sheri L. Moores, Janine Schuurman, Paul W.H.I. Parren, William R. Strohl et al. · 2021 · Journal of Biological Chemistry
74. Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
    Michael S. Glickman, Charles L. Sawyers · 2012 · Cell
75. Activating MET kinase rearrangements in melanoma and Spitz tumours
    Iwei Yeh, Thomas Botton, Eric Talevich, Alan Hunter Shain, Alyssa J. Sparatta, Arnaud de la Fouchardière, Thaddeus W. Mully, Jeffrey P. North, María C. Garrido, Alexander Gagnon et al. · 2015 · Nature Communications
76. Crizotinib in Patients With MET-Amplified NSCLC
    D. Ross Camidge, Gregory A. Otterson, Jeffrey William Clark, Sai‐Hong Ignatius Ou, Jared M. Weiss, Steven Ades, Geoffrey Ira Shapiro, Mark A. Socinski, Danielle A. Murphy, Umberto Conte et al. · 2021 · Journal of Thoracic Oncology
77. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
    Rachel M. A. Linger, Amy K. Keating, Henry Shelton Earp, Douglas K. Graham · 2010 · Expert Opinion on Therapeutic Targets
78. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
    Sima Lev · 2020 · Biochemical Society Transactions
79. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma
    Natalie I. Vokes, Emily S. Chambers, Tom T. Nguyen, Alexis Coolidge, Christine Lydon, Xiuning Le, Lynette Marie Sholl, John Victor Heymach, Mizuki Nishino, Eliezer M. Van Allen et al. · 2022 · Journal of Thoracic Oncology
80. Targeted therapies for non-small cell lung cancer
    Wolfram C. M. Dempke, Tamás Sütö, Martin Reck · 2009 · Lung Cancer
81. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
    Jin‐Ji Yang, Hua‐Jun Chen, Hong‐Hong Yan, Xu‐Chao Zhang, Qing Hua Zhou, Jian Su, Zhen Wang, Chong‐Rui Xu, Yi-Sheng Huang, Bin-Chao Wang et al. · 2012 · Lung Cancer
82. The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors
    Fei Huang, Ann Lennarson Greer, Warren W. Hurlburt, Xia Han, Rameh Hafezi, Gayle M. Wittenberg, Karen A. Reeves, Jiwen Chen, Douglas Robinson, Aixin Li et al. · 2008 · Cancer Research
83. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale
    Ravi Salgia · 2017 · Molecular Cancer Therapeutics
84. Bispecific antibody drug conjugates: Making 1+1>2
    Yilin Gu, Zhijia Wang, Yuxi Wang · 2024 · Acta Pharmaceutica Sinica B
85. Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
    Karie D. Runcie, Daniel R. Budman, Veena S. John, Nagashree Seetharamu · 2018 · Molecular Medicine
86. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
    Jill Wykosky, Tim R. Fenton, Frank B. Furnari, Webster K. Cavenee · 2011 · 癌症：英文版
87. Personalized medicine in lung cancer: what we need to know
    Tony S.K. Mok · 2011 · Nature Reviews Clinical Oncology
88. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
    Cortot, Alexis B., Jänne, Pasi A. · 2014 · European Respiratory Review
89. Seipin: from human disease to molecular mechanism
    Bethany R. Cartwright, Joel M. Goodman · 2012 · Journal of Lipid Research
90. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.
    Chunyan Ma, Shuzhen Wei, Yong Jung Song · 2011 · Europe PMC (PubMed Central)
91. Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance
    Takeshi Shimamura, Danan Li, Hongbin Ji, Henry J. Haringsma, Elizabeth Liniker, Christa L. Borgman, April M. Lowell, Yuko Minami, Kate L. McNamara, Samanthi A. Perera et al. · 2008 · Cancer Research
92. Intratumoral Heterogeneity in EGFR -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
    Margaret Soucheray, Marzia Capelletti, Inés Pulido, Yanan Kuang, Cloud Peter Paweletz, Jeffrey H. Becker, Eiki Kikuchi, Chunxiao Xu, Tarun B. Patel, Fátima Al‐Shahrour et al. · 2015 · Cancer Research
93. Emerging therapies for non-small cell lung cancer
    Chao Zhang, Natasha B. Leighl, Yi-Long Lung Cancer Wu, Wen‐Zhao Zhong · 2019 · Journal of Hematology & Oncology
94. c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas
    Koji Tsuta, Yoshiki Kozu, Takahiro Mimae, Akihiko Yoshida, Takashi Kohno, Ikuo Sekine, Tomohide Tamura, Hisao Asamura, Koh Furuta, Hitoshi Tsuda · 2011 · Journal of Thoracic Oncology
95. Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?
    A. El-Telbany, P. C. Ma · 2012 · Genes & Cancer
96. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
    Maria Clemence Schwaederle, Hatim Husain, Paul Timothy Fanta, David Eric Piccioni, Santosh Kesari, Richard B. Schwab, Kimberly C. Banks, Richard Burnham Lanman, AmirAli H. Talasaz, Barbara A. Parker et al. · 2016 · Oncotarget
97. Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways
    Xiangqi Meng, Yu Zhao, Bo Ram Han, Caijun Zha, Yangong Zhang, Ziwei Li, Pengfei Wu, Tengfei Qi, Chuanlu Jiang, Yang Liu et al. · 2020 · Nature Communications
98. Overcoming implementation challenges of personalized cancer therapy
    Funda Meric‐Bernstam, Gordon Brent Mills · 2012 · Nature Reviews Clinical Oncology
99. ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence
    Jieyi Wang, Mark G. Anderson, Anatol Oleksijew, Kedar S. Vaidya, Erwin R. Boghaert, Lora A. Tucker, Qian Yun Zhang, Edward Kyu-Ho Han, Joann P. Palma, Louie Naumovski et al. · 2016 · Clinical Cancer Research
100. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
     Bin-Chi Liao, Chia‐Chi Lin, James Chih‐Hsin Yang · 2015 · Current Opinion in Oncology